Press Releases

Press Releases

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience


Milestones in MERS Vaccine Research and Development

2016-10-10 02:18

Milestones in MERS Vaccine Research and Development

  • IVI hosts International MERS-CoV Symposium, convening top scientists and experts in public health, infectious diseases and vaccine development

  • IVI to embark on MERS vaccine development project with funding from Samsung


September 10, 2015, Seoul, Republic of Korea – The International Vaccine Institute (IVI), the Seoul-based international organization, hosts the “2015 Shinil-IVI Global Vaccine Forum: International MERS-CoV Symposium” at the Novotel Ambassador Gangnam in Seoul today. The institute also announced it will launch initiatives to develop vaccines against Middle East Respiratory Syndrome (MERS), following the September 2nd announcement made by Samsung Medical Center that it would donate 41 billion Korean won (34 million USD) to IVI over the next five years to find a MERS vaccine.


“As an international organization dedicated to discovering, developing and delivering vaccines for global public health, we are very excited to start work on MERS, a disease that has become a concern in South Korea and worldwide,” said Dr. Jerome Kim, IVI’s Director General, “Gathering the world’s preeminent scientists and experts on MERS at the symposium and especially the Samsung funding are significant boosts in global efforts to develop vaccines against MERS.”  


MERS is a viral respiratory illness caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). First detected in 2012 in Saudi Arabia, it has been reported in several countries, causing 1,478 cases and 516 deaths globally, including a recent major outbreak in South Korea with 185 cases and 36 deaths. Currently there is no vaccine or antiretroviral treatment for MERS-CoV infection. 


With support from Samsung, IVI will lead an international collaboration to advance the development of MERS vaccines as quickly and safely as possible. IVI is in the process of identifying the most promising vaccine candidates and is under discussion with groups that have vaccines ready for human testing and that have data from animal studies suggesting the vaccine may protect against MERS disease.


Sponsored by Shinil and the Korea Support Committee for IVI (KSC), the one-day symposium convenes leading scientists and experts in public health, infectious diseases and vaccine development from Korea, China, Europe, the Middle East and the United States where they will present the latest translational and clinical research and discuss opportunities for the development of MERS-CoV countermeasures, particularly vaccines.


Speakers include the Deputy Minister of Health of Saudi Arabia and representatives from the U.S. Centers for Disease Control and Prevention, Walter Reed Army Institute of Research, World Health Organization, Erasmus Medical Center of the Netherlands, Seoul National University, Fudan University, Institut Pasteur Korea, Inovio, GeneOne, Regeneron, and Novovax. His Excellency Mark W. Lippert, the U.S Ambassador to the Republic of Korea, will give the keynote speech.


“I would like to thank all those who made the symposium possible, including our sponsors, Shinil and KSC,” said Dr. Kim, “I particularly would like to express my deep gratitude to Samsung for their very generous contribution and confidence in IVI. With their support, we will harness the best resources and capabilities in Korea and internationally to accelerate the development of new, safe and effective MERS vaccines.” 




About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to discovering, developing and delivering new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research at its headquarters in Seoul, Republic of Korea and in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, as well as dengue fever. For more information, please visit



Media Contact:



Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-11-9773-6071



Burson-Marsteller Korea Contact:

Minkyoung Kim

Phone: +82-2-3782-6471

Mobile: +82-10-9161=2520



Nayoung Kim

Phone: +82-2-3782-6458

Mobile: +82-10-8967-1909